WO2011054995A3 - Vaccins prophylactiques contre la grippe obtenus à partir de capsides virales de birnavirus contenant l'antigène m2e du virus de la grippe - Google Patents

Vaccins prophylactiques contre la grippe obtenus à partir de capsides virales de birnavirus contenant l'antigène m2e du virus de la grippe Download PDF

Info

Publication number
WO2011054995A3
WO2011054995A3 PCT/ES2010/070716 ES2010070716W WO2011054995A3 WO 2011054995 A3 WO2011054995 A3 WO 2011054995A3 ES 2010070716 W ES2010070716 W ES 2010070716W WO 2011054995 A3 WO2011054995 A3 WO 2011054995A3
Authority
WO
WIPO (PCT)
Prior art keywords
flu
birnavirus
antigen
prophylactic
vaccines
Prior art date
Application number
PCT/ES2010/070716
Other languages
English (en)
Spanish (es)
Other versions
WO2011054995A2 (fr
Inventor
Thomas Zurcher
Cayetano Von Kobbe
Juan José BERNAL
Ignacio JIMÉNEZ TORRES
María VELA CUENCA
Ana Diaz Blazquez
Miguel Angel Llamas Matias
Diana Martin Lorenzo
Arcadio GARCÍA DE CASTRO
Original Assignee
Chimera Pharma, S. L. U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimera Pharma, S. L. U. filed Critical Chimera Pharma, S. L. U.
Publication of WO2011054995A2 publication Critical patent/WO2011054995A2/fr
Publication of WO2011054995A3 publication Critical patent/WO2011054995A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/10011Birnaviridae
    • C12N2720/10023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des vaccins prophylactiques pour la prévention de la grippe chez les êtres humains. En particulier, les vaccins de la présente invention sont formés de capsides pseudo-virales chimériques de birnavirus contenant l'antigène M2e du virus de la grippe.
PCT/ES2010/070716 2009-11-06 2010-11-05 Vaccins prophylactiques contre la grippe obtenus à partir de capsides virales de birnavirus contenant l'antigène m2e du virus de la grippe WO2011054995A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200930968 2009-11-06
ES200930968 2009-11-06

Publications (2)

Publication Number Publication Date
WO2011054995A2 WO2011054995A2 (fr) 2011-05-12
WO2011054995A3 true WO2011054995A3 (fr) 2011-06-30

Family

ID=43806896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070716 WO2011054995A2 (fr) 2009-11-06 2010-11-05 Vaccins prophylactiques contre la grippe obtenus à partir de capsides virales de birnavirus contenant l'antigène m2e du virus de la grippe

Country Status (1)

Country Link
WO (1) WO2011054995A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059168A2 (fr) * 2011-10-21 2013-04-25 Research Development Foundation Virus espirito santo et procédés de détection et de prévention d'une infection par ledit virus
CN103083656A (zh) * 2011-10-27 2013-05-08 苏州科贝生物技术有限公司 甲型流感病毒保守肽M2e与病毒样颗粒的缀合物及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887412A1 (fr) * 1997-05-26 1998-12-30 Akzo Nobel N.V. Vaccin recombinant du birnavirus
WO2002088339A2 (fr) * 2001-05-02 2002-11-07 Institut National De La Recherche Agronomique (Inra) Particules pseudovirales de birnavirus
WO2007009673A1 (fr) * 2005-07-15 2007-01-25 Consejo Superior De Investigaciones Científicas Particules chimeriques vides d'apparence virale tirees du virus de la bursite infectieuse (ibdv), procede de production et applications
EP1752468A1 (fr) * 2004-04-30 2007-02-14 Consejo Superior de Investigaciones Cientificas Procede de production de capsules virales vides en levure composees de proteines derivees de pvp2 du virus entrainant la maladie de la bursite infectieuse (ibdv)
WO2007020017A1 (fr) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition destinee a l'immunisation des oiseaux et administree par aerosol
WO2009026465A2 (fr) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition et procédés de fabrication et d'utilisation de protéines de la grippe
WO2009135518A1 (fr) * 2008-05-09 2009-11-12 Chimera Pharma S.L.U. Protéines de fusion chimères et particules de type viral de birnavirus vp2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297786C (fr) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887412A1 (fr) * 1997-05-26 1998-12-30 Akzo Nobel N.V. Vaccin recombinant du birnavirus
WO2002088339A2 (fr) * 2001-05-02 2002-11-07 Institut National De La Recherche Agronomique (Inra) Particules pseudovirales de birnavirus
EP1752468A1 (fr) * 2004-04-30 2007-02-14 Consejo Superior de Investigaciones Cientificas Procede de production de capsules virales vides en levure composees de proteines derivees de pvp2 du virus entrainant la maladie de la bursite infectieuse (ibdv)
WO2007009673A1 (fr) * 2005-07-15 2007-01-25 Consejo Superior De Investigaciones Científicas Particules chimeriques vides d'apparence virale tirees du virus de la bursite infectieuse (ibdv), procede de production et applications
WO2007020017A1 (fr) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition destinee a l'immunisation des oiseaux et administree par aerosol
WO2009026465A2 (fr) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition et procédés de fabrication et d'utilisation de protéines de la grippe
WO2009135518A1 (fr) * 2008-05-09 2009-11-12 Chimera Pharma S.L.U. Protéines de fusion chimères et particules de type viral de birnavirus vp2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LETZEL TOBIAS ET AL: "Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 81, no. 23, 1 December 2007 (2007-12-01), pages 12827 - 12835, XP002514417, ISSN: 0022-538X, [retrieved on 20070919], DOI: DOI:10.1128/JVI.01501.07 *
REMOND M ET AL: "Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 1, 1 January 2009 (2009-01-01), pages 93 - 98, XP025714114, ISSN: 0264-410X, [retrieved on 20081105], DOI: DOI:10.1016/J.VACCINE.2008.10.036 *
VAN LOON A A W M ET AL: "Alteration of amino acids in VP2 of very virulent infectious bursal disease virus results in tissue culture adaptation and attenuation in chickens", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 83, no. 1, 1 January 2002 (2002-01-01), pages 121 - 129, XP002514415, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
WO2011054995A2 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
HRP20180706T1 (hr) Kimerna gripa nalik čestici koja sadrži hemaglutinin
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
AP2012006075A0 (en) Production of polio virus at high titers for vaccine production.
IL210451A (en) Epitope for influenza virus vaccine
WO2011103453A3 (fr) Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
IN2014CN02114A (fr)
BRPI0912285A2 (pt) anticorpos monoclonais tendo propriedades de neutralização cruzada de homosubtipo contra o vírus influenza subtipo h1.
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
PT2635257T (pt) Partículas semelhantes a vírus de glicoproteína de raiva (vlps)
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
WO2012137227A3 (fr) Formes solides de composés antirétroviraux, procédé de préparation correspondant et composition pharmaceutique de ces composés
BRPI1007584A2 (pt) vacina de sarampo-malária combinada, vetor de vírus de vacina de sarampo, hospedeiro e composição de vacina de sarampo-malária combinada
WO2014145245A3 (fr) Procédés et compositions pour des épitopes de blocage de norovirus
EP2897628A4 (fr) Nouvelles souches atténuées du virus de la dengue destinées à une application de vaccin
WO2012058493A3 (fr) Protéine d'hémagglutinine recombinante du virus de la grippe et vaccin la contenant
EP2484757A4 (fr) Virus capable d'exprimer un épitope de -galactose, et procédé de production de vaccin
WO2011054995A3 (fr) Vaccins prophylactiques contre la grippe obtenus à partir de capsides virales de birnavirus contenant l'antigène m2e du virus de la grippe
WO2014008475A3 (fr) Compositions et procédés associés à des vaccins viraux
SG11201403773WA (en) Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
EP3247390A4 (fr) Immunogénicité d'un vaccin à adn consensus synthétique optimisé pour le virus de la diarrhée épidémique porcine
WO2009117736A3 (fr) Vaccins contre virus aviaires et leurs utilisations
WO2014188212A3 (fr) Traitement et prévention du paludisme
TH1201001748B (th) ส่วนสร้างที่สามารถผลิตแคปสิดเปล่าของไวรัส
TH112917B (th) โปรตีนให้การเชื่อมจับ และ elisa ทำการบล็อค-อีพิโทปสำหรับการตรวจหาโดยทั่วไปของไวรัสไข้หวัดใหญ่ประเภทย่อย h5

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809272

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 10809272

Country of ref document: EP

Kind code of ref document: A2